Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, TRI, FVT

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science



ORCHARD PARK, N.Y., Dec. 7, 2017 /PRNewswire/ -- Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.

"We're dedicated to the wide dissemination of scientific advances to improve understanding and spur future discoveries," said Mikhail Blagosklonny, Oncotarget's editor-in-chief. "The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting."

The sponsored researchers presented studies ranging from assessing the impact of drug treatments on kidney cancer to characterizing the chemoresistance of asbestos-related tumors.  The researchers and their presentations are as follows:

The FCS 2017 conference, which was held November 6 ? 8th, was hosted by seven major research institutes: Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology and Lee Kong Chian School of Medicine.

For more biomedical research in oncology and related areas such as immunology and microbiology, the latest issue of Oncotarget is available at http://www.impactjournals.com/oncotarget.

About Oncotarget

Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact Information:

Ryan James Jessup
Rapamycin Press
202-638-9720
RyanJamesJessup@RapamycinPress.com

 

SOURCE Oncotarget


These press releases may also interest you

at 04:00
The 2016 WHO report on 'Cause of death in the world' revealed that heart related deaths accounted for 31% of the total deaths, costing 1.7 million lives. As the number of death caused by cardiac arrest is increasing, the demand for automated external...

at 03:30
NEW YORK, Oct. 23, 2018 /PRNewswire-PRWeb/ -- Can a simple change in diet make all the difference, such as cutting down on sugar? Could obesity, diabetes, and other diseases be the result of a bad diet? Is alternative medicine the answer? Dr. Derrick...

at 03:08
Johnson & Johnson today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare...

at 03:00
Moringa Wellness, South African manufacturers of a unique Moringa-based product line powered with the company's secret ingredient, Moringex; continues to show its corporate social responsibility efforts by sponsoring the Ray Wilson Memorial Chisamba...

at 03:00
Acquisition further establishes High Hampton's position as a vertical integrator of the California cannabis market, and will provide near-term revenue in adult use and medical extract markets /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES...

at 03:00
PITTSBURGH, Pa., Oct. 23, 2018 /PRNewswire-PRWeb/ -- Virtual assistants, like Apple's Siri and Amazon's Alexa, have quickly become a part of the daily lives of many healthcare professionals throughout the country, but "What about similar technology...




News published on 7 december 2017 at 14:36 and distributed by: